nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR2—uterine cancer	0.414	1	CbGaD
Ponatinib—ABCB11—Progesterone—uterine cancer	0.0681	0.227	CbGbCtD
Ponatinib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.026	0.0867	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—uterine cancer	0.0257	0.0855	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—uterine cancer	0.0208	0.0693	CbGbCtD
Ponatinib—CYP3A5—Progesterone—uterine cancer	0.0179	0.0598	CbGbCtD
Ponatinib—ABCG2—Carboplatin—uterine cancer	0.0173	0.0575	CbGbCtD
Ponatinib—CYP2C8—Progesterone—uterine cancer	0.0173	0.0575	CbGbCtD
Ponatinib—ABCG2—Etoposide—uterine cancer	0.0145	0.0483	CbGbCtD
Ponatinib—ABCB1—Progesterone—uterine cancer	0.0117	0.0389	CbGbCtD
Ponatinib—CYP2D6—Progesterone—uterine cancer	0.011	0.0366	CbGbCtD
Ponatinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0106	0.0352	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—uterine cancer	0.00989	0.0329	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—uterine cancer	0.00926	0.0308	CbGbCtD
Ponatinib—CYP3A5—Etoposide—uterine cancer	0.00803	0.0267	CbGbCtD
Ponatinib—CYP2C8—Etoposide—uterine cancer	0.00772	0.0257	CbGbCtD
Ponatinib—CYP3A4—Progesterone—uterine cancer	0.007	0.0233	CbGbCtD
Ponatinib—ABCB1—Etoposide—uterine cancer	0.00523	0.0174	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—uterine cancer	0.00356	0.0119	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—uterine cancer	0.00336	0.0112	CbGbCtD
Ponatinib—CYP3A4—Etoposide—uterine cancer	0.00313	0.0104	CbGbCtD
Ponatinib—CYP3A4—Doxorubicin—uterine cancer	0.00214	0.00711	CbGbCtD
Ponatinib—TEK—artery—uterine cancer	0.00156	0.0228	CbGeAlD
Ponatinib—FGFR4—Podofilox—Etoposide—uterine cancer	0.00154	0.582	CbGdCrCtD
Ponatinib—FGFR2—exocrine gland—uterine cancer	0.00142	0.0207	CbGeAlD
Ponatinib—SRC—artery—uterine cancer	0.00139	0.0203	CbGeAlD
Ponatinib—FGFR4—renal system—uterine cancer	0.00128	0.0187	CbGeAlD
Ponatinib—KDR—artery—uterine cancer	0.00127	0.0186	CbGeAlD
Ponatinib—BCR—myometrium—uterine cancer	0.00104	0.0152	CbGeAlD
Ponatinib—FGFR4—female reproductive system—uterine cancer	0.00103	0.015	CbGeAlD
Ponatinib—KIT—exocrine gland—uterine cancer	0.000985	0.0144	CbGeAlD
Ponatinib—FGFR3—epithelium—uterine cancer	0.000942	0.0138	CbGeAlD
Ponatinib—FGFR3—uterine cervix—uterine cancer	0.000934	0.0137	CbGeAlD
Ponatinib—FGFR4—female gonad—uterine cancer	0.000934	0.0136	CbGeAlD
Ponatinib—FGFR1—myometrium—uterine cancer	0.000924	0.0135	CbGeAlD
Ponatinib—FGFR3—renal system—uterine cancer	0.000874	0.0128	CbGeAlD
Ponatinib—FGFR3—mammalian vulva—uterine cancer	0.000818	0.0119	CbGeAlD
Ponatinib—BCR—uterine cervix—uterine cancer	0.000809	0.0118	CbGeAlD
Ponatinib—BCR—decidua—uterine cancer	0.00077	0.0113	CbGeAlD
Ponatinib—BCR—renal system—uterine cancer	0.000756	0.0111	CbGeAlD
Ponatinib—BCR—endometrium—uterine cancer	0.000731	0.0107	CbGeAlD
Ponatinib—FGFR1—uterine cervix—uterine cancer	0.000719	0.0105	CbGeAlD
Ponatinib—BCR—mammalian vulva—uterine cancer	0.000707	0.0103	CbGeAlD
Ponatinib—FGFR3—female reproductive system—uterine cancer	0.0007	0.0102	CbGeAlD
Ponatinib—FGFR1—decidua—uterine cancer	0.000685	0.01	CbGeAlD
Ponatinib—BCR—uterus—uterine cancer	0.000674	0.00985	CbGeAlD
Ponatinib—RET—epithelium—uterine cancer	0.000649	0.00949	CbGeAlD
Ponatinib—LCK—uterine cervix—uterine cancer	0.000644	0.00941	CbGeAlD
Ponatinib—FGFR1—mammalian vulva—uterine cancer	0.000629	0.0092	CbGeAlD
Ponatinib—FGFR2—epithelium—uterine cancer	0.000617	0.00902	CbGeAlD
Ponatinib—KDR—myometrium—uterine cancer	0.000616	0.009	CbGeAlD
Ponatinib—RET—decidua—uterine cancer	0.000613	0.00896	CbGeAlD
Ponatinib—LCK—decidua—uterine cancer	0.000613	0.00896	CbGeAlD
Ponatinib—FGFR2—uterine cervix—uterine cancer	0.000612	0.00894	CbGeAlD
Ponatinib—BCR—female reproductive system—uterine cancer	0.000606	0.00885	CbGeAlD
Ponatinib—RET—renal system—uterine cancer	0.000602	0.0088	CbGeAlD
Ponatinib—FLT3—female reproductive system—uterine cancer	0.000601	0.00879	CbGeAlD
Ponatinib—FGFR4—lymph node—uterine cancer	0.0006	0.00877	CbGeAlD
Ponatinib—FGFR1—uterus—uterine cancer	0.0006	0.00876	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—uterine cancer	0.000594	0.00869	CbGeAlD
Ponatinib—TEK—epithelium—uterine cancer	0.000591	0.00864	CbGeAlD
Ponatinib—FGFR2—renal system—uterine cancer	0.000572	0.00836	CbGeAlD
Ponatinib—TEK—smooth muscle tissue—uterine cancer	0.00057	0.00833	CbGeAlD
Ponatinib—LCK—mammalian vulva—uterine cancer	0.000563	0.00823	CbGeAlD
Ponatinib—TEK—decidua—uterine cancer	0.000559	0.00817	CbGeAlD
Ponatinib—BCR—female gonad—uterine cancer	0.000551	0.00806	CbGeAlD
Ponatinib—TEK—renal system—uterine cancer	0.000549	0.00802	CbGeAlD
Ponatinib—BCR—vagina—uterine cancer	0.000548	0.00801	CbGeAlD
Ponatinib—FLT3—female gonad—uterine cancer	0.000547	0.008	CbGeAlD
Ponatinib—KIT—myometrium—uterine cancer	0.000546	0.00798	CbGeAlD
Ponatinib—LCK—uterus—uterine cancer	0.000537	0.00784	CbGeAlD
Ponatinib—TEK—endometrium—uterine cancer	0.00053	0.00775	CbGeAlD
Ponatinib—SRC—epithelium—uterine cancer	0.000525	0.00768	CbGeAlD
Ponatinib—SRC—uterine cervix—uterine cancer	0.000521	0.00761	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—uterine cancer	0.000516	0.00755	CbGeAlD
Ponatinib—FGFR2—uterus—uterine cancer	0.00051	0.00745	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—uterine cancer	0.000506	0.0074	CbGeAlD
Ponatinib—PDGFRA—decidua—uterine cancer	0.000506	0.0074	CbGeAlD
Ponatinib—PDGFRA—renal system—uterine cancer	0.000497	0.00726	CbGeAlD
Ponatinib—SRC—decidua—uterine cancer	0.000496	0.00725	CbGeAlD
Ponatinib—FGFR1—female gonad—uterine cancer	0.00049	0.00717	CbGeAlD
Ponatinib—TEK—uterus—uterine cancer	0.000489	0.00714	CbGeAlD
Ponatinib—FGFR1—vagina—uterine cancer	0.000487	0.00712	CbGeAlD
Ponatinib—SRC—renal system—uterine cancer	0.000487	0.00712	CbGeAlD
Ponatinib—KDR—epithelium—uterine cancer	0.000483	0.00706	CbGeAlD
Ponatinib—KDR—uterine cervix—uterine cancer	0.000479	0.007	CbGeAlD
Ponatinib—ABL1—myometrium—uterine cancer	0.000475	0.00694	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—uterine cancer	0.000466	0.00681	CbGeAlD
Ponatinib—FGFR2—female reproductive system—uterine cancer	0.000458	0.0067	CbGeAlD
Ponatinib—KDR—decidua—uterine cancer	0.000457	0.00667	CbGeAlD
Ponatinib—KDR—renal system—uterine cancer	0.000448	0.00655	CbGeAlD
Ponatinib—PDGFRA—uterus—uterine cancer	0.000443	0.00647	CbGeAlD
Ponatinib—TEK—female reproductive system—uterine cancer	0.000439	0.00642	CbGeAlD
Ponatinib—LCK—female gonad—uterine cancer	0.000439	0.00641	CbGeAlD
Ponatinib—LCK—vagina—uterine cancer	0.000436	0.00638	CbGeAlD
Ponatinib—KDR—endometrium—uterine cancer	0.000433	0.00634	CbGeAlD
Ponatinib—KIT—epithelium—uterine cancer	0.000428	0.00626	CbGeAlD
Ponatinib—KIT—uterine cervix—uterine cancer	0.000425	0.00621	CbGeAlD
Ponatinib—KDR—mammalian vulva—uterine cancer	0.000419	0.00613	CbGeAlD
Ponatinib—FGFR2—female gonad—uterine cancer	0.000417	0.00609	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—uterine cancer	0.000413	0.00603	CbGeAlD
Ponatinib—KIT—decidua—uterine cancer	0.000405	0.00591	CbGeAlD
Ponatinib—TEK—female gonad—uterine cancer	0.0004	0.00584	CbGeAlD
Ponatinib—KDR—uterus—uterine cancer	0.000399	0.00584	CbGeAlD
Ponatinib—PDGFRA—female reproductive system—uterine cancer	0.000398	0.00582	CbGeAlD
Ponatinib—KIT—renal system—uterine cancer	0.000397	0.00581	CbGeAlD
Ponatinib—SRC—female reproductive system—uterine cancer	0.00039	0.0057	CbGeAlD
Ponatinib—KIT—endometrium—uterine cancer	0.000384	0.00561	CbGeAlD
Ponatinib—KIT—mammalian vulva—uterine cancer	0.000372	0.00543	CbGeAlD
Ponatinib—ABL1—uterine cervix—uterine cancer	0.00037	0.0054	CbGeAlD
Ponatinib—PDGFRA—female gonad—uterine cancer	0.000362	0.00529	CbGeAlD
Ponatinib—PDGFRA—vagina—uterine cancer	0.00036	0.00526	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—uterine cancer	0.000359	0.00525	CbGeAlD
Ponatinib—KDR—female reproductive system—uterine cancer	0.000359	0.00525	CbGeAlD
Ponatinib—SRC—female gonad—uterine cancer	0.000355	0.00519	CbGeAlD
Ponatinib—BCR—lymph node—uterine cancer	0.000354	0.00518	CbGeAlD
Ponatinib—KIT—uterus—uterine cancer	0.000354	0.00517	CbGeAlD
Ponatinib—ABL1—decidua—uterine cancer	0.000352	0.00515	CbGeAlD
Ponatinib—FLT3—lymph node—uterine cancer	0.000352	0.00514	CbGeAlD
Ponatinib—ABL1—renal system—uterine cancer	0.000346	0.00506	CbGeAlD
Ponatinib—ABL1—endometrium—uterine cancer	0.000334	0.00489	CbGeAlD
Ponatinib—KDR—female gonad—uterine cancer	0.000327	0.00478	CbGeAlD
Ponatinib—KDR—vagina—uterine cancer	0.000325	0.00475	CbGeAlD
Ponatinib—ABL1—mammalian vulva—uterine cancer	0.000323	0.00473	CbGeAlD
Ponatinib—KIT—female reproductive system—uterine cancer	0.000318	0.00465	CbGeAlD
Ponatinib—FGFR1—lymph node—uterine cancer	0.000315	0.00461	CbGeAlD
Ponatinib—ABL1—uterus—uterine cancer	0.000308	0.0045	CbGeAlD
Ponatinib—ABCG2—myometrium—uterine cancer	0.0003	0.00438	CbGeAlD
Ponatinib—KIT—female gonad—uterine cancer	0.00029	0.00423	CbGeAlD
Ponatinib—KIT—vagina—uterine cancer	0.000288	0.00421	CbGeAlD
Ponatinib—RET—lymph node—uterine cancer	0.000282	0.00412	CbGeAlD
Ponatinib—LCK—lymph node—uterine cancer	0.000282	0.00412	CbGeAlD
Ponatinib—ABL1—female reproductive system—uterine cancer	0.000277	0.00405	CbGeAlD
Ponatinib—TEK—lymph node—uterine cancer	0.000257	0.00376	CbGeAlD
Ponatinib—ABL1—female gonad—uterine cancer	0.000252	0.00368	CbGeAlD
Ponatinib—ABL1—vagina—uterine cancer	0.000251	0.00366	CbGeAlD
Ponatinib—ABCG2—uterine cervix—uterine cancer	0.000233	0.00341	CbGeAlD
Ponatinib—PDGFRA—lymph node—uterine cancer	0.000233	0.0034	CbGeAlD
Ponatinib—SRC—lymph node—uterine cancer	0.000228	0.00334	CbGeAlD
Ponatinib—CYP2C8—renal system—uterine cancer	0.000224	0.00328	CbGeAlD
Ponatinib—ABCG2—decidua—uterine cancer	0.000222	0.00325	CbGeAlD
Ponatinib—CYP2C8—endometrium—uterine cancer	0.000217	0.00317	CbGeAlD
Ponatinib—CYP3A5—uterine cervix—uterine cancer	0.000216	0.00316	CbGeAlD
Ponatinib—ABCG2—endometrium—uterine cancer	0.000211	0.00308	CbGeAlD
Ponatinib—KDR—lymph node—uterine cancer	0.00021	0.00307	CbGeAlD
Ponatinib—ABCG2—mammalian vulva—uterine cancer	0.000204	0.00298	CbGeAlD
Ponatinib—CYP3A5—renal system—uterine cancer	0.000202	0.00296	CbGeAlD
Ponatinib—ABCG2—uterus—uterine cancer	0.000194	0.00284	CbGeAlD
Ponatinib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.000192	0.0724	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.000192	0.0724	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.000192	0.0724	CbGdCrCtD
Ponatinib—KIT—lymph node—uterine cancer	0.000186	0.00272	CbGeAlD
Ponatinib—CYP2C8—female reproductive system—uterine cancer	0.00018	0.00263	CbGeAlD
Ponatinib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000177	0.067	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000177	0.067	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000177	0.067	CbGdCrCtD
Ponatinib—CYP2C8—vagina—uterine cancer	0.000162	0.00237	CbGeAlD
Ponatinib—ABL1—lymph node—uterine cancer	0.000162	0.00237	CbGeAlD
Ponatinib—ABCG2—female gonad—uterine cancer	0.000159	0.00232	CbGeAlD
Ponatinib—ABCG2—vagina—uterine cancer	0.000158	0.00231	CbGeAlD
Ponatinib—CYP3A4—renal system—uterine cancer	0.000152	0.00222	CbGeAlD
Ponatinib—CYP2D6—renal system—uterine cancer	0.00015	0.00219	CbGeAlD
Ponatinib—ABCB1—myometrium—uterine cancer	0.000148	0.00216	CbGeAlD
Ponatinib—CYP3A5—female gonad—uterine cancer	0.000148	0.00216	CbGeAlD
Ponatinib—CYP3A5—vagina—uterine cancer	0.000147	0.00214	CbGeAlD
Ponatinib—CYP3A4—female reproductive system—uterine cancer	0.000122	0.00178	CbGeAlD
Ponatinib—CYP2D6—female reproductive system—uterine cancer	0.00012	0.00175	CbGeAlD
Ponatinib—ABCB1—epithelium—uterine cancer	0.000116	0.00169	CbGeAlD
Ponatinib—ABCB1—uterine cervix—uterine cancer	0.000115	0.00168	CbGeAlD
Ponatinib—Cardiac disorder—Etoposide—uterine cancer	0.000112	0.00109	CcSEcCtD
Ponatinib—Dizziness—Progesterone—uterine cancer	0.000111	0.00108	CcSEcCtD
Ponatinib—ABCB1—decidua—uterine cancer	0.00011	0.0016	CbGeAlD
Ponatinib—Angiopathy—Etoposide—uterine cancer	0.00011	0.00107	CcSEcCtD
Ponatinib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000109	0.00106	CcSEcCtD
Ponatinib—CYP2D6—female gonad—uterine cancer	0.000109	0.00159	CbGeAlD
Ponatinib—Mediastinal disorder—Etoposide—uterine cancer	0.000109	0.00106	CcSEcCtD
Ponatinib—Chills—Etoposide—uterine cancer	0.000108	0.00106	CcSEcCtD
Ponatinib—Sepsis—Doxorubicin—uterine cancer	0.000108	0.00105	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000108	0.00105	CcSEcCtD
Ponatinib—Cardiac failure congestive—Epirubicin—uterine cancer	0.000108	0.00105	CcSEcCtD
Ponatinib—ABCB1—renal system—uterine cancer	0.000108	0.00157	CbGeAlD
Ponatinib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000107	0.00105	CcSEcCtD
Ponatinib—Alopecia—Etoposide—uterine cancer	0.000107	0.00104	CcSEcCtD
Ponatinib—Vomiting—Progesterone—uterine cancer	0.000107	0.00104	CcSEcCtD
Ponatinib—Rash—Progesterone—uterine cancer	0.000106	0.00103	CcSEcCtD
Ponatinib—Dermatitis—Progesterone—uterine cancer	0.000106	0.00103	CcSEcCtD
Ponatinib—Headache—Progesterone—uterine cancer	0.000105	0.00102	CcSEcCtD
Ponatinib—Hot flush—Epirubicin—uterine cancer	0.000105	0.00102	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000104	0.00101	CcSEcCtD
Ponatinib—ABCB1—endometrium—uterine cancer	0.000104	0.00152	CbGeAlD
Ponatinib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000104	0.00101	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000104	0.00101	CcSEcCtD
Ponatinib—Menopausal symptoms—Epirubicin—uterine cancer	0.000104	0.00101	CcSEcCtD
Ponatinib—Decreased appetite—Dactinomycin—uterine cancer	0.000103	0.001	CcSEcCtD
Ponatinib—ABCG2—lymph node—uterine cancer	0.000102	0.00149	CbGeAlD
Ponatinib—Fatigue—Dactinomycin—uterine cancer	0.000102	0.000996	CcSEcCtD
Ponatinib—Back pain—Etoposide—uterine cancer	0.000102	0.000991	CcSEcCtD
Ponatinib—Pain—Dactinomycin—uterine cancer	0.000101	0.000988	CcSEcCtD
Ponatinib—Muscle spasms—Etoposide—uterine cancer	0.000101	0.000985	CcSEcCtD
Ponatinib—ABCB1—mammalian vulva—uterine cancer	0.000101	0.00147	CbGeAlD
Ponatinib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.0001	0.000979	CcSEcCtD
Ponatinib—Cardiac failure—Epirubicin—uterine cancer	0.0001	0.000977	CcSEcCtD
Ponatinib—Cerebrovascular accident—Epirubicin—uterine cancer	9.98e-05	0.000973	CcSEcCtD
Ponatinib—Lethargy—Epirubicin—uterine cancer	9.98e-05	0.000973	CcSEcCtD
Ponatinib—Cardiac failure congestive—Doxorubicin—uterine cancer	9.98e-05	0.000973	CcSEcCtD
Ponatinib—Nausea—Progesterone—uterine cancer	9.96e-05	0.000971	CcSEcCtD
Ponatinib—Hyponatraemia—Epirubicin—uterine cancer	9.82e-05	0.000957	CcSEcCtD
Ponatinib—Pain in extremity—Epirubicin—uterine cancer	9.78e-05	0.000954	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	9.78e-05	0.000954	CcSEcCtD
Ponatinib—Anaemia—Etoposide—uterine cancer	9.71e-05	0.000947	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dactinomycin—uterine cancer	9.69e-05	0.000945	CcSEcCtD
Ponatinib—Hot flush—Doxorubicin—uterine cancer	9.67e-05	0.000943	CcSEcCtD
Ponatinib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	9.66e-05	0.000942	CcSEcCtD
Ponatinib—Migraine—Epirubicin—uterine cancer	9.63e-05	0.000939	CcSEcCtD
Ponatinib—Menopausal symptoms—Doxorubicin—uterine cancer	9.59e-05	0.000935	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Doxorubicin—uterine cancer	9.59e-05	0.000935	CcSEcCtD
Ponatinib—ABCB1—uterus—uterine cancer	9.58e-05	0.0014	CbGeAlD
Ponatinib—Rash—Medroxyprogesterone Acetate—uterine cancer	9.58e-05	0.000934	CcSEcCtD
Ponatinib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	9.57e-05	0.000933	CcSEcCtD
Ponatinib—Headache—Medroxyprogesterone Acetate—uterine cancer	9.52e-05	0.000928	CcSEcCtD
Ponatinib—Face oedema—Epirubicin—uterine cancer	9.44e-05	0.000921	CcSEcCtD
Ponatinib—Leukopenia—Etoposide—uterine cancer	9.41e-05	0.000917	CcSEcCtD
Ponatinib—Abdominal pain—Dactinomycin—uterine cancer	9.37e-05	0.000913	CcSEcCtD
Ponatinib—Body temperature increased—Dactinomycin—uterine cancer	9.37e-05	0.000913	CcSEcCtD
Ponatinib—Cardiac failure—Doxorubicin—uterine cancer	9.27e-05	0.000904	CcSEcCtD
Ponatinib—Cerebrovascular accident—Doxorubicin—uterine cancer	9.24e-05	0.0009	CcSEcCtD
Ponatinib—Lethargy—Doxorubicin—uterine cancer	9.24e-05	0.0009	CcSEcCtD
Ponatinib—Cough—Etoposide—uterine cancer	9.17e-05	0.000894	CcSEcCtD
Ponatinib—Blood creatinine increased—Epirubicin—uterine cancer	9.16e-05	0.000893	CcSEcCtD
Ponatinib—Dehydration—Epirubicin—uterine cancer	9.1e-05	0.000887	CcSEcCtD
Ponatinib—Hyponatraemia—Doxorubicin—uterine cancer	9.09e-05	0.000886	CcSEcCtD
Ponatinib—Hypertension—Etoposide—uterine cancer	9.07e-05	0.000884	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	9.05e-05	0.000882	CcSEcCtD
Ponatinib—Pain in extremity—Doxorubicin—uterine cancer	9.05e-05	0.000882	CcSEcCtD
Ponatinib—Nausea—Medroxyprogesterone Acetate—uterine cancer	9.02e-05	0.00088	CcSEcCtD
Ponatinib—Dry skin—Epirubicin—uterine cancer	8.97e-05	0.000874	CcSEcCtD
Ponatinib—Migraine—Doxorubicin—uterine cancer	8.91e-05	0.000868	CcSEcCtD
Ponatinib—Hypokalaemia—Epirubicin—uterine cancer	8.9e-05	0.000868	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	8.88e-05	0.000866	CcSEcCtD
Ponatinib—Breast disorder—Epirubicin—uterine cancer	8.84e-05	0.000862	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	8.81e-05	0.000859	CcSEcCtD
Ponatinib—Nasopharyngitis—Epirubicin—uterine cancer	8.75e-05	0.000853	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—uterine cancer	8.74e-05	0.000852	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	8.63e-05	0.000841	CcSEcCtD
Ponatinib—ABCB1—female reproductive system—uterine cancer	8.61e-05	0.00126	CbGeAlD
Ponatinib—Infection—Etoposide—uterine cancer	8.52e-05	0.000831	CcSEcCtD
Ponatinib—Abdominal distension—Epirubicin—uterine cancer	8.51e-05	0.00083	CcSEcCtD
Ponatinib—Asthenia—Dactinomycin—uterine cancer	8.5e-05	0.000829	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—uterine cancer	8.48e-05	0.000827	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—uterine cancer	8.42e-05	0.00082	CcSEcCtD
Ponatinib—Thrombocytopenia—Etoposide—uterine cancer	8.4e-05	0.000819	CcSEcCtD
Ponatinib—Skin disorder—Etoposide—uterine cancer	8.33e-05	0.000812	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—uterine cancer	8.3e-05	0.000809	CcSEcCtD
Ponatinib—Hyperhidrosis—Etoposide—uterine cancer	8.29e-05	0.000808	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—uterine cancer	8.29e-05	0.000808	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—uterine cancer	8.24e-05	0.000803	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—uterine cancer	8.23e-05	0.000803	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—uterine cancer	8.18e-05	0.000797	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	8.15e-05	0.000794	CcSEcCtD
Ponatinib—Diarrhoea—Dactinomycin—uterine cancer	8.11e-05	0.00079	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—uterine cancer	8.09e-05	0.000789	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—uterine cancer	8.03e-05	0.000783	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	7.98e-05	0.000778	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—uterine cancer	7.9e-05	0.000771	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—uterine cancer	7.87e-05	0.000768	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—uterine cancer	7.86e-05	0.000766	CcSEcCtD
Ponatinib—ABCB1—female gonad—uterine cancer	7.84e-05	0.00115	CbGeAlD
Ponatinib—ABCB1—vagina—uterine cancer	7.79e-05	0.00114	CbGeAlD
Ponatinib—Paraesthesia—Etoposide—uterine cancer	7.7e-05	0.000751	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—uterine cancer	7.67e-05	0.000748	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—uterine cancer	7.65e-05	0.000746	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—uterine cancer	7.65e-05	0.000745	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—uterine cancer	7.63e-05	0.000743	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—uterine cancer	7.62e-05	0.000743	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—uterine cancer	7.58e-05	0.000739	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—uterine cancer	7.54e-05	0.000735	CcSEcCtD
Ponatinib—Infestation—Epirubicin—uterine cancer	7.54e-05	0.000735	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—uterine cancer	7.53e-05	0.000734	CcSEcCtD
Ponatinib—Rash—Dactinomycin—uterine cancer	7.47e-05	0.000728	CcSEcCtD
Ponatinib—Decreased appetite—Etoposide—uterine cancer	7.46e-05	0.000727	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—uterine cancer	7.43e-05	0.000724	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—uterine cancer	7.4e-05	0.000722	CcSEcCtD
Ponatinib—Fatigue—Etoposide—uterine cancer	7.39e-05	0.000721	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—uterine cancer	7.39e-05	0.00072	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—uterine cancer	7.35e-05	0.000716	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—uterine cancer	7.35e-05	0.000716	CcSEcCtD
Ponatinib—Constipation—Etoposide—uterine cancer	7.33e-05	0.000715	CcSEcCtD
Ponatinib—Pain—Etoposide—uterine cancer	7.33e-05	0.000715	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—uterine cancer	7.33e-05	0.000714	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—uterine cancer	7.31e-05	0.000713	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—uterine cancer	7.27e-05	0.000709	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—uterine cancer	7.13e-05	0.000695	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—uterine cancer	7.11e-05	0.000693	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—uterine cancer	7.08e-05	0.00069	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—uterine cancer	7.06e-05	0.000688	CcSEcCtD
Ponatinib—Nausea—Dactinomycin—uterine cancer	7.04e-05	0.000686	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—uterine cancer	7.01e-05	0.000684	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—uterine cancer	7.01e-05	0.000684	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—uterine cancer	6.97e-05	0.00068	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—uterine cancer	6.97e-05	0.00068	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—uterine cancer	6.84e-05	0.000666	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—uterine cancer	6.8e-05	0.000663	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—uterine cancer	6.8e-05	0.000663	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—uterine cancer	6.8e-05	0.000663	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—uterine cancer	6.78e-05	0.000661	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—uterine cancer	6.78e-05	0.000661	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—uterine cancer	6.78e-05	0.000661	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—uterine cancer	6.77e-05	0.00066	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—uterine cancer	6.73e-05	0.000656	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—uterine cancer	6.67e-05	0.00065	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—uterine cancer	6.65e-05	0.000648	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—uterine cancer	6.6e-05	0.000643	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—uterine cancer	6.58e-05	0.000641	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—uterine cancer	6.52e-05	0.000636	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—uterine cancer	6.32e-05	0.000616	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—uterine cancer	6.29e-05	0.000613	CcSEcCtD
Ponatinib—Flushing—Epirubicin—uterine cancer	6.28e-05	0.000612	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—uterine cancer	6.28e-05	0.000612	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—uterine cancer	6.26e-05	0.00061	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—uterine cancer	6.23e-05	0.000607	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—uterine cancer	6.17e-05	0.000601	CcSEcCtD
Ponatinib—Asthenia—Etoposide—uterine cancer	6.15e-05	0.0006	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—uterine cancer	6.15e-05	0.0006	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—uterine cancer	6.14e-05	0.000598	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—uterine cancer	6.1e-05	0.000594	CcSEcCtD
Ponatinib—Chills—Epirubicin—uterine cancer	6.07e-05	0.000592	CcSEcCtD
Ponatinib—Pruritus—Etoposide—uterine cancer	6.07e-05	0.000592	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—uterine cancer	6.04e-05	0.000589	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—uterine cancer	6.03e-05	0.000588	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—uterine cancer	5.98e-05	0.000583	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—uterine cancer	5.93e-05	0.000578	CcSEcCtD
Ponatinib—Erythema—Epirubicin—uterine cancer	5.89e-05	0.000574	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—uterine cancer	5.89e-05	0.000574	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—uterine cancer	5.87e-05	0.000572	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—uterine cancer	5.85e-05	0.00057	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—uterine cancer	5.81e-05	0.000566	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—uterine cancer	5.81e-05	0.000566	CcSEcCtD
Ponatinib—Back pain—Epirubicin—uterine cancer	5.7e-05	0.000555	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—uterine cancer	5.68e-05	0.000554	CcSEcCtD
Ponatinib—Dizziness—Etoposide—uterine cancer	5.67e-05	0.000553	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—uterine cancer	5.66e-05	0.000552	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—uterine cancer	5.64e-05	0.00055	CcSEcCtD
Ponatinib—Chills—Doxorubicin—uterine cancer	5.62e-05	0.000548	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—uterine cancer	5.59e-05	0.000545	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—uterine cancer	5.55e-05	0.000541	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—uterine cancer	5.53e-05	0.000539	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—uterine cancer	5.49e-05	0.000535	CcSEcCtD
Ponatinib—Vomiting—Etoposide—uterine cancer	5.45e-05	0.000532	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—uterine cancer	5.45e-05	0.000531	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—uterine cancer	5.45e-05	0.000531	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—uterine cancer	5.44e-05	0.000531	CcSEcCtD
Ponatinib—Rash—Etoposide—uterine cancer	5.41e-05	0.000527	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—uterine cancer	5.4e-05	0.000527	CcSEcCtD
Ponatinib—Headache—Etoposide—uterine cancer	5.37e-05	0.000524	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—uterine cancer	5.27e-05	0.000514	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—uterine cancer	5.27e-05	0.000514	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—uterine cancer	5.24e-05	0.000511	CcSEcCtD
Ponatinib—Cough—Epirubicin—uterine cancer	5.14e-05	0.000501	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—uterine cancer	5.14e-05	0.000501	CcSEcCtD
Ponatinib—Nausea—Etoposide—uterine cancer	5.09e-05	0.000497	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—uterine cancer	5.09e-05	0.000496	CcSEcCtD
Ponatinib—ABCB1—lymph node—uterine cancer	5.04e-05	0.000736	CbGeAlD
Ponatinib—Anaemia—Doxorubicin—uterine cancer	5.04e-05	0.000491	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—uterine cancer	5.01e-05	0.000489	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—uterine cancer	5.01e-05	0.000489	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	4.98e-05	0.000486	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—uterine cancer	4.9e-05	0.000478	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—uterine cancer	4.88e-05	0.000476	CcSEcCtD
Ponatinib—Oedema—Epirubicin—uterine cancer	4.81e-05	0.000469	CcSEcCtD
Ponatinib—Infection—Epirubicin—uterine cancer	4.78e-05	0.000466	CcSEcCtD
Ponatinib—Cough—Doxorubicin—uterine cancer	4.76e-05	0.000464	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—uterine cancer	4.71e-05	0.00046	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—uterine cancer	4.71e-05	0.000459	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—uterine cancer	4.71e-05	0.000459	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—uterine cancer	4.67e-05	0.000455	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—uterine cancer	4.65e-05	0.000453	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—uterine cancer	4.64e-05	0.000452	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—uterine cancer	4.64e-05	0.000452	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	4.61e-05	0.000449	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—uterine cancer	4.54e-05	0.000442	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—uterine cancer	4.45e-05	0.000434	CcSEcCtD
Ponatinib—Infection—Doxorubicin—uterine cancer	4.42e-05	0.000431	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—uterine cancer	4.38e-05	0.000427	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—uterine cancer	4.36e-05	0.000425	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—uterine cancer	4.36e-05	0.000425	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—uterine cancer	4.35e-05	0.000424	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—uterine cancer	4.32e-05	0.000421	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—uterine cancer	4.32e-05	0.000421	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—uterine cancer	4.3e-05	0.000419	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—uterine cancer	4.29e-05	0.000418	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—uterine cancer	4.23e-05	0.000413	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—uterine cancer	4.18e-05	0.000407	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—uterine cancer	4.15e-05	0.000405	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—uterine cancer	4.14e-05	0.000404	CcSEcCtD
Ponatinib—Pain—Epirubicin—uterine cancer	4.11e-05	0.000401	CcSEcCtD
Ponatinib—Constipation—Epirubicin—uterine cancer	4.11e-05	0.000401	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	4.05e-05	0.000395	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—uterine cancer	4.02e-05	0.000392	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—uterine cancer	3.99e-05	0.000389	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—uterine cancer	3.97e-05	0.000387	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—uterine cancer	3.93e-05	0.000383	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—uterine cancer	3.92e-05	0.000382	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—uterine cancer	3.87e-05	0.000377	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	3.84e-05	0.000374	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—uterine cancer	3.83e-05	0.000374	CcSEcCtD
Ponatinib—Pain—Doxorubicin—uterine cancer	3.8e-05	0.000371	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—uterine cancer	3.8e-05	0.000371	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—uterine cancer	3.8e-05	0.00037	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—uterine cancer	3.8e-05	0.00037	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—uterine cancer	3.64e-05	0.000355	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—uterine cancer	3.52e-05	0.000343	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—uterine cancer	3.52e-05	0.000343	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—uterine cancer	3.45e-05	0.000336	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—uterine cancer	3.4e-05	0.000332	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—uterine cancer	3.29e-05	0.000321	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—uterine cancer	3.19e-05	0.000311	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—uterine cancer	3.18e-05	0.00031	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—uterine cancer	3.15e-05	0.000307	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—uterine cancer	3.06e-05	0.000298	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—uterine cancer	3.04e-05	0.000297	CcSEcCtD
Ponatinib—Rash—Epirubicin—uterine cancer	3.03e-05	0.000295	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—uterine cancer	3.03e-05	0.000295	CcSEcCtD
Ponatinib—Headache—Epirubicin—uterine cancer	3.01e-05	0.000294	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—uterine cancer	2.94e-05	0.000287	CcSEcCtD
Ponatinib—Nausea—Epirubicin—uterine cancer	2.86e-05	0.000278	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—uterine cancer	2.83e-05	0.000276	CcSEcCtD
Ponatinib—Rash—Doxorubicin—uterine cancer	2.8e-05	0.000273	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—uterine cancer	2.8e-05	0.000273	CcSEcCtD
Ponatinib—Headache—Doxorubicin—uterine cancer	2.79e-05	0.000272	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—uterine cancer	2.64e-05	0.000258	CcSEcCtD
Ponatinib—CYP2C8—Metabolism—STK11—uterine cancer	3.22e-06	2.87e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP19A1—uterine cancer	3.22e-06	2.87e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCL2—uterine cancer	3.21e-06	2.86e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ERBB2—uterine cancer	3.2e-06	2.86e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—uterine cancer	3.19e-06	2.84e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—uterine cancer	3.18e-06	2.84e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—AKT1—uterine cancer	3.18e-06	2.84e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AKT1—uterine cancer	3.15e-06	2.81e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—NRAS—uterine cancer	3.15e-06	2.81e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NRAS—uterine cancer	3.14e-06	2.81e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CDKN1B—uterine cancer	3.14e-06	2.8e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NRAS—uterine cancer	3.13e-06	2.8e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—ERBB2—uterine cancer	3.13e-06	2.8e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—EP300—uterine cancer	3.13e-06	2.79e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—uterine cancer	3.11e-06	2.78e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KRAS—uterine cancer	3.11e-06	2.77e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—PIK3CA—uterine cancer	3.1e-06	2.77e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCL8—uterine cancer	3.09e-06	2.76e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGFR2—uterine cancer	3.09e-06	2.76e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KRAS—uterine cancer	3.08e-06	2.75e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POLD1—uterine cancer	3.08e-06	2.75e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KRAS—uterine cancer	3.07e-06	2.74e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KRAS—uterine cancer	3.05e-06	2.72e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB2—uterine cancer	3.04e-06	2.71e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL8—uterine cancer	3.04e-06	2.71e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—PIK3CA—uterine cancer	3.04e-06	2.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB2—uterine cancer	3.03e-06	2.71e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CDKN1B—uterine cancer	3.02e-06	2.7e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.02e-06	2.69e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB2—uterine cancer	3e-06	2.68e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—KRAS—uterine cancer	3e-06	2.67e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ESR1—uterine cancer	2.99e-06	2.67e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—PIK3CA—uterine cancer	2.98e-06	2.66e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—PIK3CA—uterine cancer	2.98e-06	2.66e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CDKN1B—uterine cancer	2.97e-06	2.65e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CTNNB1—uterine cancer	2.97e-06	2.65e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CDKN1B—uterine cancer	2.9e-06	2.59e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PTEN—uterine cancer	2.89e-06	2.58e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL8—uterine cancer	2.88e-06	2.57e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.88e-06	2.57e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.88e-06	2.57e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL8—uterine cancer	2.88e-06	2.57e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—uterine cancer	2.87e-06	2.56e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—AKT1—uterine cancer	2.87e-06	2.56e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—AKT1—uterine cancer	2.86e-06	2.55e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CTNNB1—uterine cancer	2.85e-06	2.55e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PIK3CA—uterine cancer	2.85e-06	2.55e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—uterine cancer	2.84e-06	2.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—uterine cancer	2.84e-06	2.53e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—PIK3CA—uterine cancer	2.83e-06	2.53e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—PIK3CA—uterine cancer	2.82e-06	2.52e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CDKN1B—uterine cancer	2.82e-06	2.51e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—uterine cancer	2.81e-06	2.51e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN1B—uterine cancer	2.81e-06	2.51e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—uterine cancer	2.81e-06	2.51e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CTNNB1—uterine cancer	2.8e-06	2.5e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PIK3CA—uterine cancer	2.8e-06	2.5e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP19A1—uterine cancer	2.8e-06	2.5e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—STK11—uterine cancer	2.8e-06	2.5e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MTHFR—uterine cancer	2.79e-06	2.49e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTEN—uterine cancer	2.78e-06	2.48e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CDKN1B—uterine cancer	2.78e-06	2.48e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB2—uterine cancer	2.77e-06	2.47e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—uterine cancer	2.76e-06	2.46e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—uterine cancer	2.76e-06	2.46e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EP300—uterine cancer	2.76e-06	2.46e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—uterine cancer	2.76e-06	2.46e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PIK3CA—uterine cancer	2.75e-06	2.46e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—uterine cancer	2.75e-06	2.45e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CTNNB1—uterine cancer	2.74e-06	2.45e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTEN—uterine cancer	2.73e-06	2.44e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—uterine cancer	2.71e-06	2.42e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—uterine cancer	2.71e-06	2.42e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—uterine cancer	2.7e-06	2.41e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB2—uterine cancer	2.68e-06	2.39e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTEN—uterine cancer	2.67e-06	2.38e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CTNNB1—uterine cancer	2.66e-06	2.37e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CTNNB1—uterine cancer	2.65e-06	2.37e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EP300—uterine cancer	2.65e-06	2.37e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ESR1—uterine cancer	2.64e-06	2.36e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—STK11—uterine cancer	2.64e-06	2.36e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP19A1—uterine cancer	2.64e-06	2.36e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—uterine cancer	2.64e-06	2.36e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL2—uterine cancer	2.63e-06	2.35e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CTNNB1—uterine cancer	2.63e-06	2.34e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—uterine cancer	2.62e-06	2.34e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—uterine cancer	2.61e-06	2.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—uterine cancer	2.61e-06	2.33e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EP300—uterine cancer	2.61e-06	2.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—uterine cancer	2.61e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTEN—uterine cancer	2.59e-06	2.31e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—uterine cancer	2.59e-06	2.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTEN—uterine cancer	2.59e-06	2.31e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—uterine cancer	2.58e-06	2.3e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1B—uterine cancer	2.57e-06	2.29e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—RRM2—uterine cancer	2.57e-06	2.29e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PTEN—uterine cancer	2.56e-06	2.29e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—uterine cancer	2.55e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EP300—uterine cancer	2.55e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—uterine cancer	2.54e-06	2.26e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—uterine cancer	2.53e-06	2.26e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—uterine cancer	2.51e-06	2.24e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DCN—uterine cancer	2.49e-06	2.22e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—uterine cancer	2.49e-06	2.22e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—uterine cancer	2.49e-06	2.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—uterine cancer	2.48e-06	2.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—uterine cancer	2.48e-06	2.21e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—uterine cancer	2.48e-06	2.21e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1B—uterine cancer	2.48e-06	2.21e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EP300—uterine cancer	2.47e-06	2.21e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—uterine cancer	2.47e-06	2.2e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EP300—uterine cancer	2.47e-06	2.2e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EP300—uterine cancer	2.44e-06	2.18e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—uterine cancer	2.44e-06	2.18e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—uterine cancer	2.44e-06	2.17e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—uterine cancer	2.43e-06	2.17e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CTNNB1—uterine cancer	2.43e-06	2.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—uterine cancer	2.42e-06	2.16e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—uterine cancer	2.42e-06	2.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—uterine cancer	2.41e-06	2.15e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—uterine cancer	2.4e-06	2.15e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—uterine cancer	2.38e-06	2.13e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—uterine cancer	2.36e-06	2.11e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.35e-06	2.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—uterine cancer	2.34e-06	2.09e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—uterine cancer	2.34e-06	2.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—uterine cancer	2.34e-06	2.09e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—uterine cancer	2.33e-06	2.08e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL2—uterine cancer	2.33e-06	2.08e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—uterine cancer	2.31e-06	2.06e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—uterine cancer	2.31e-06	2.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—uterine cancer	2.31e-06	2.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—uterine cancer	2.31e-06	2.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—uterine cancer	2.31e-06	2.06e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—uterine cancer	2.3e-06	2.06e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—uterine cancer	2.3e-06	2.05e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—uterine cancer	2.29e-06	2.05e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—uterine cancer	2.29e-06	2.04e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—uterine cancer	2.28e-06	2.04e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—uterine cancer	2.28e-06	2.04e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EP300—uterine cancer	2.25e-06	2.01e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—uterine cancer	2.25e-06	2.01e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—uterine cancer	2.22e-06	1.98e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.22e-06	1.98e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—uterine cancer	2.19e-06	1.96e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EP300—uterine cancer	2.18e-06	1.94e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—uterine cancer	2.17e-06	1.93e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—uterine cancer	2.14e-06	1.91e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—uterine cancer	2.13e-06	1.9e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.13e-06	1.9e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—uterine cancer	2.13e-06	1.9e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—uterine cancer	2.11e-06	1.88e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—uterine cancer	2.11e-06	1.88e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—uterine cancer	2.1e-06	1.87e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—uterine cancer	2.08e-06	1.86e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—EP300—uterine cancer	2.07e-06	1.84e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—uterine cancer	2.06e-06	1.84e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—uterine cancer	2.05e-06	1.83e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—uterine cancer	2.04e-06	1.82e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—uterine cancer	2.04e-06	1.82e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—uterine cancer	2.03e-06	1.82e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—uterine cancer	2.03e-06	1.81e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—uterine cancer	2.03e-06	1.81e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—uterine cancer	2.02e-06	1.81e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—uterine cancer	1.99e-06	1.78e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—uterine cancer	1.99e-06	1.77e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—uterine cancer	1.98e-06	1.77e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—uterine cancer	1.97e-06	1.75e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—uterine cancer	1.96e-06	1.75e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—uterine cancer	1.94e-06	1.73e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—uterine cancer	1.93e-06	1.72e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—uterine cancer	1.92e-06	1.71e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—uterine cancer	1.9e-06	1.69e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—uterine cancer	1.89e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—uterine cancer	1.89e-06	1.68e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—uterine cancer	1.88e-06	1.68e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—uterine cancer	1.87e-06	1.67e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—uterine cancer	1.86e-06	1.66e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—uterine cancer	1.84e-06	1.64e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—uterine cancer	1.83e-06	1.63e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—uterine cancer	1.82e-06	1.63e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—uterine cancer	1.82e-06	1.62e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—uterine cancer	1.82e-06	1.62e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—uterine cancer	1.81e-06	1.61e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—uterine cancer	1.8e-06	1.6e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—uterine cancer	1.78e-06	1.59e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EP300—uterine cancer	1.78e-06	1.59e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—uterine cancer	1.77e-06	1.58e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—uterine cancer	1.77e-06	1.58e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—uterine cancer	1.75e-06	1.56e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—uterine cancer	1.74e-06	1.56e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—STK11—uterine cancer	1.73e-06	1.54e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.73e-06	1.54e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—uterine cancer	1.7e-06	1.52e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—uterine cancer	1.69e-06	1.51e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—uterine cancer	1.69e-06	1.51e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—uterine cancer	1.69e-06	1.51e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—uterine cancer	1.67e-06	1.49e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—uterine cancer	1.67e-06	1.49e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—uterine cancer	1.67e-06	1.49e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—uterine cancer	1.67e-06	1.49e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—uterine cancer	1.66e-06	1.48e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—uterine cancer	1.61e-06	1.44e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—uterine cancer	1.6e-06	1.43e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EP300—uterine cancer	1.58e-06	1.41e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—uterine cancer	1.57e-06	1.41e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—uterine cancer	1.56e-06	1.39e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—uterine cancer	1.55e-06	1.39e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—uterine cancer	1.54e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—uterine cancer	1.54e-06	1.37e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—uterine cancer	1.53e-06	1.36e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—uterine cancer	1.5e-06	1.33e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—uterine cancer	1.49e-06	1.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—uterine cancer	1.49e-06	1.33e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—uterine cancer	1.49e-06	1.33e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—EP300—uterine cancer	1.48e-06	1.32e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—uterine cancer	1.48e-06	1.32e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—uterine cancer	1.48e-06	1.32e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—uterine cancer	1.44e-06	1.28e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—uterine cancer	1.36e-06	1.22e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—uterine cancer	1.34e-06	1.2e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—uterine cancer	1.32e-06	1.18e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—uterine cancer	1.31e-06	1.17e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—uterine cancer	1.3e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—EP300—uterine cancer	1.28e-06	1.14e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—uterine cancer	1.28e-06	1.14e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—uterine cancer	1.27e-06	1.13e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—uterine cancer	1.25e-06	1.11e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—uterine cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—uterine cancer	1.17e-06	1.05e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—uterine cancer	1.17e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—uterine cancer	1.13e-06	1.01e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—EP300—uterine cancer	1.12e-06	9.97e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—uterine cancer	1.1e-06	9.85e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—uterine cancer	1.1e-06	9.77e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—uterine cancer	1.08e-06	9.64e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—uterine cancer	1.08e-06	9.62e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—EP300—uterine cancer	1.05e-06	9.4e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—uterine cancer	9.54e-07	8.52e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—uterine cancer	9.48e-07	8.47e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—uterine cancer	8.95e-07	7.98e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—uterine cancer	8.26e-07	7.38e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—uterine cancer	7.79e-07	6.95e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—uterine cancer	7.75e-07	6.92e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—uterine cancer	7.22e-07	6.44e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—EP300—uterine cancer	6.88e-07	6.14e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—uterine cancer	6.75e-07	6.03e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—uterine cancer	6.36e-07	5.68e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.09e-07	4.54e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—uterine cancer	4.16e-07	3.71e-06	CbGpPWpGaD
